Magenta Therapeutics appoints Michael Vasconcelles to board; CMO Jeffrey Humphrey departs

Dianthus Therapeutics, Inc. /DE/

Michael Vasconcelles, M.D. appointed to board, filling vacancy from Alexis Borisy not being reelected.
Vasconcelles brings 30+ years in oncology; served as CMO at Flatiron Health and Unum Therapeutics.
Chief Medical Officer Jeffrey Humphrey parted ways on August 15, 2022, not due to disagreement.
Shawn Rose, M.D., Ph.D., appointed SVP and Head of Clinical Development effective immediately.
Rose joined Magenta in February 2022; previously at Annexon, Janssen, and Bristol Myers Squibb.

item 5.02 item 7.01 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Michael Vasconcelles

Director

DNTH · Dianthus Therapeutics, Inc. /DE/

Effective: 2022-08-15
Filed: August 17, 2022, 7:59 PM ET

On August 15, 2022, the Board of Directors (the “Board”) of Magenta Therapeutics, Inc. (the “Company”) unanimously appointed Michael Vasconcelles to the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Michael Vasconcelles was appointed as Director at Dianthus Therapeutics, Inc. /DE/.

Action: appointed
Role: Director

Exact text from the filing

On August 15, 2022, the Board of Directors (the “Board”) of Magenta Therapeutics, Inc. (the “Company”) unanimously appointed Michael Vasconcelles to the Board.

View on SEC.gov

Dianthus Therapeutics, Inc. /DE/ filing history →

Source: SEC EDGAR

accession 0001193125-22-222823

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.